Global expansion Solvias has expanded to six global facilities with a recent US expansion in 2025, signaling a growing capacity to support multinational clients and regional bioscience clusters. This presents selling opportunities to pharmaceutical and biotech firms seeking robust CMC analytics support across therapeutic areas.

Sustainability edge EcoVadis Bronze Medal and top 35% ranking reflect a formal sustainability program and external validation. This can be leveraged to engage sustainability‑mocused manufacturers and vendors who require compliant supply chains and ESG credentials.

Strategic partnerships Longstanding collaboration with Vertex Pharmaceuticals on CRISPR/Cas9 edited cell therapies demonstrates Solvias’ expertise in advanced modalities and regulatory‑grade analytics, suggesting opportunities with gene therapy and cell therapy developers seeking reliable analytical release testing.

End‑to‑end partner Positioning as a single trusted analytical partner from raw materials to final release testing across small molecules, biologics, and cell therapies creates cross‑sell potential for customers expanding their development pipelines or moving into new modalities.

Quality and compliance focus GMP, GLP, and ISO certifications plus conducting over 100 customer audits annually highlight a strong quality and compliance backbone, enabling sales conversations with highly regulated biopharma manufacturers who require rigorous analytics partners to shorten time to market.